1-3 of 3
Frédéric Maloisel, MD
Close
Sort by
Journal Articles

EOSTA: An Observational Study on the Compliance and Quality of Life (QoL) of Chronic Myeloid Leukemia (CML) Patients Treated with Second Line Nilotinib (Tasigna®) : Interim Results At 6 Months of Follow-up,

Delphine Rea, MD, PhD, Frédéric Maloisel, MD, Françoise Huguet, MD, Hikaru Okada, MD, PhD, Isabelle Bourdeix, Franck E. Nicolini, MD, PhD, Michel Tulliez, Gabriel Etienne, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3782.
https://doi.org/10.1182/blood.V118.21.3782.3782
Published: 2011
Journal Articles

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

Franck E. Nicolini, MD, PhD, Emmanuel Bachy, MD, Sélim Corm, MD, Quoc-Hung Lê, MD, Sandrine Hayette, PhD, Dominique Bories, MD, PhD, Michel Tulliez, MD, Nathalie Sorel, MD, Francois Guilhot, MD, Laurence Legros, MD, François-Xavier Mahon, MD, PhD, Frédéric Maloisel, MD, Jean-Jacques Kiladjian, MD, PhD, Catherine Roche-Lestienne, PhD, Claude Preudhomme, MD, PhD, Mauricette Michallet, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 2190.
https://doi.org/10.1182/blood.V108.11.2190.2190
Published: 2006
Journal Articles

Autologous Stem Cell Transplantation (ASCT) Versus Standard Treatments for CLL Patients: First Interim Analysis of a Prospective Randomized Study from the French Cooperative Study Group on CLL.

Laurent Sutton, MD, Marine Diviné, MD, Philippe Travade, MD, Claude Martin, MD, Stéphane Leprêtre, MD, Hugo Gonzalez, MD, Eric Van den Neste, MD, Mauricette Michallet, MD, Florence Cymbalista, MD, Frédéric Maloisel, MD, Véronique Leblond, MD, Houchingue Eghbali, MD, Michel Berthout, MD, Didier Decaudin, MD, Brigitte Dreyfus, MD, Bruno Cazin, MD, Krimo Bouabdallah, MD, Anne Drihème Pharm, Hélène Merle-Béral, MD, Michel Leporrier, MD
Journal: Blood
Blood (2005) 106 (11): 5471.
https://doi.org/10.1182/blood.V106.11.5471.5471
Published: 2005